Find something to look at
Browse by category, see the connections as a graph, check out what's being tested in patients right now, or see the latest FDA approvals.
Disease ↔ gene ↔ drug
See the connections as a graph
Three things connect everything: diseases, the genes involved in them, and the drugs that act on those genes. Pick a disease and we'll draw the picture: which genes drive it, and which existing drugs hit those genes.
By category
Pick a body system or disease family. Click any condition to see drugs that might also help it.
Cancer
Solid tumors, blood cancers, and rare oncology.
Heart & vessels
Cardiovascular disease, blood pressure, clotting.
Brain & nerves
Neurodegeneration, dementia, movement, headache.
Mental health
Mood, anxiety, attention, addiction.
Immune & autoimmune
When the body's defenses go wrong.
Metabolism & weight
Diabetes, obesity, thyroid, liver, hormones.
Drugs being tested in patients right now
The most-recent Phase II / Phase III studies that are actively recruiting people. Pulled live from ClinicalTrials.gov.
- Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravuli…PHASE3For: Delayed Graft Function, DGF +1 moreRavulizumabPlaceboNCT06830798● recruiting
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve…PHASE3For: Metastatic Castration-resistant Prostate CancerXaluritamigAbiraterone acetateDocetaxelCabazitaxelNCT07213674● recruiting
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comor…PHASE3For: Obesity, OverweightOrforglipronPlaceboNCT06672939● recruiting
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)PHASE3For: Obesity, Weight GainTirzepatidePlaceboNCT06439277● recruiting
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic L…PHASE3For: Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaObinutuzumabVenetoclaxNCT04269902● recruiting
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive P…PHASE3For: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma +4 moreDoxorubicinPembrolizumabNCT06422806● recruiting
- Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune ThrombocytopeniaPHASE2, PHASE3For: Systemic Lupus Erythematosus, Immune ThrombocytopeniaSirolimusPlaceboNCT07657793● recruiting
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal No…PHASE3For: Paroxysmal Nocturnal HemoglobinuriaPozelimabCemdisiranNCT07154745● recruiting
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy A…PHASE3For: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver +2 moreBevacizumabCetuximabFloxuridineFluorouracilNCT05863195● recruiting
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With…PHASE3For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)LY3650150PlaceboStandard therapy for IN…NCT06338995● recruiting
- Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMPPHASE2, PHASE3For: Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt PhenomenonSirolimus (RAPAMUNE)NCT07656909● recruiting
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, a…PHASE2, PHASE3For: Metastatic Pancreatic Ductal Adenocarcinoma, PDACTelisotuzumab adizutecanFluorouracilFolinic acid/ Leucovori…OxaliplatinNCT07490301● recruiting
Notable recent FDA approvals
A hand-picked tour of new medicines that reached patients in the last couple of years. Click into any one to see what else it might also help.
Leqembi
2023lecanemabApproved for early Alzheimer's disease.First antibody to slow Alzheimer's progression, by clearing amyloid plaques from the brain.
See its profile →Kisunla
2024donanemabApproved for early Alzheimer's disease.Second-generation amyloid antibody — limited-duration treatment, stops once plaques clear.
See its profile →Rezdiffra
2024resmetiromApproved for advanced fatty liver disease (MASH).First drug ever approved for non-alcoholic steatohepatitis — a condition affecting tens of millions.
See its profile →Zepbound
2023tirzepatideApproved for obesity.GLP-1/GIP dual receptor agonist; the most effective weight-loss medication in trials to date.
See its profile →Winrevair
2024sotaterceptApproved for pulmonary arterial hypertension.First-in-class activin signaling inhibitor for a rare, progressive lung condition.
See its profile →Amtagvi
2024lifileucelApproved for advanced melanoma.First cellular therapy for a solid tumor — uses the patient's own T cells against the cancer.
See its profile →Truqap
2023capivasertibApproved for HR+/HER2- breast cancer.Targets the AKT pathway in tumors that have become resistant to hormone therapy.
See its profile →Wegovy
2024semaglutideApproved for cardiovascular risk reduction.Already approved for obesity; new indication shows it cuts heart-attack risk in overweight adults.
See its profile →